Impact of Genetic Factors (CYP2C9, VKORC1 and CYP4F2) on Warfarin Dose Requirement in the Turkish Population

Basic and Clinical Pharmacology and Toxicology

Volumn 112, Issue 3, 2013, Pages 209-214

  Özer, Mahmut ^a   Demirci, Yeliz ^a   Hizel, Candan ^b,c,d   Sarikaya, Sabit ^e   Karalti, Iskender ^a   Kaspar, Çiǧdem ^a   Alpan, Serdar ^a   Genç, Ece ^a  

^a YEDITEPE UNIVERSITY   (Turkey)

^b ANADOLU UNIVERSITY   (Turkey)

^c C2H Vichy Genomics   (France)

^d Bulgulu Mahallesi   (Turkey)

^e Kartal Kosuyolu Education and Research Hospital   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 2C9; CYTOCHROME P450 4F2; EPOXIDE HYDROLASE; EPOXIDE HYDROLASE 1; GENOMIC DNA; OXIDOREDUCTASE; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE; WARFARIN;

ADULT; AGE; AGED; ALCOHOL CONSUMPTION; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BLOOD SAMPLING; DNA ISOLATION; FEMALE; FOOD INTAKE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; POPULATION GENETICS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SMOKING; TURKEY (REPUBLIC); VEGETABLE; VENOUS THROMBOEMBOLISM;

ADULT; AGED; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 ENZYME SYSTEM; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; EPOXIDE HYDROLASES; FEMALE; GENOTYPE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; POLYMORPHISM, SINGLE NUCLEOTIDE; REGRESSION ANALYSIS; TURKEY; WARFARIN;

EID: 84873732970     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/bcpt.12024     Document Type: Article

References (32)

1. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:160S-98S.
2. Baglin TP, Cousins D, Keeling DM, Perry DJ, Watson HG. Safety indicators for inpatient and outpatient oral anticoagulant care: [corrected] Recommendations from the British Committee for Standards in Haematology and National Patient Safety Agency. Br J Haematol 2007;136:26-9.
3. Flockhart DA, O'Kane D, Williams MS, Watson MS, Gage B, Gandolfi R et al. Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genet Med 2008;10:139-50.
4. Husted SE, Ziegler BK, Kher A. Long-term anticoagulant therapy in patients with coronary artery disease. Eur Heart J 2006;27:913-9.
5. Singer DE, Albers GW, Dalen JE, Fang MC, Go AS, Halperin JL et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:546S-92S.
6. Gage BF, Eby CS. Pharmacogenetics and anticoagulant therapy. J Thromb Thrombolysis 2003;16:73-8.
7. Daly AK, King BP. Pharmacogenetics of oral anticoagulants. Pharmacogenetics 2003;13:247-52.
8. Takahashi H, Echizen H. Pharmacogenetics of warfarin elimination and its clinical implications. Clin Pharmacokinet 2001;40:587-603.
9. Takahashi H, Wilkinson GR, Nutescu EA, Morita T, Ritchie MD, Scordo MG et al. Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet Genomics 2006;16:101-10.
10. D'Andrea G, D'Ambrosio RL, Di Perna P, Chetta M, Santacroce R, Brancaccio V et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 2005;105:645-9.
11. Rost S, Fregin A, Ivaskevicius V, Conzelmann E, Hortnagel K, Pelz HJ et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 2004;427:537-41.
12. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005;352:2285-93.
13. Oner Ozgon G, Langaee TY, Feng H, Buyru N, Ulutin T, Hatemi AC et al. VKORC1 and CYP2C9 polymorphisms are associated with warfarin dose requirements in Turkish patients. Eur J Clin Pharmacol 2008;64:889-94.
14. Ozer N, Cam N, Tangurek B, Ozer S, Uyarel H, Oz D et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements in an adult Turkish population. Heart Vessels 2010;25:155-62.
15. Caldwell MD, Awad T, Johnson JA, Gage BF, Falkowski M, Gardina P et al. CYP4F2 genetic variant alters required warfarin dose. Blood 2008;111:4106-12.
16. Wadelius M, Chen LY, Eriksson N, Bumpstead S, Ghori J, Wadelius C et al. Association of warfarin dose with genes involved in its action and metabolism. Hum Genet 2007;121:23-34.
17. Wadelius M, Chen LY, Lindh JD, Eriksson N, Ghori MJ, Bumpstead S et al. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 2009;113:784-92.
18. Gage BF, Eby C, Johnson JA, Deych E, Rieder MJ, Ridker PM et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther 2008;84:326-31.
19. Schwarz UI, Ritchie MD, Bradford Y, Li C, Dudek SM, Frye-Anderson A et al. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 2008;358:999-1008.
20. Takeuchi F, McGinnis R, Bourgeois S, Barnes C, Eriksson N, Soranzo N et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet 2009;5:e1000433.
21. Lee MT, Chen CH, Chou CH, Lu LS, Chuang HP, Chen YT et al. Genetic determinants of warfarin dosing in the Han-Chinese population. Pharmacogenomics 2009;10:1905-13.
22. Loebstein R, Vecsler M, Kurnik D, Austerweil N, Gak E, Halkin H et al. Common genetic variants of microsomal epoxide hydrolase affect warfarin dose requirements beyond the effect of cytochrome P450 2C9. Clin Pharmacol Ther 2005;77:365-72.
23. Morisseau C, Hammock BD. Epoxide hydrolases: mechanisms, inhibitor designs, and biological roles. Annu Rev Pharmacol Toxicol 2005;45:311-33.
24. Pautas E, Moreau C, Gouin-Thibault I, Golmard JL, Mahe I, Legendre C et al. Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients. Clin Pharmacol Ther 2010;87:57-64.
25. Cha PC, Mushiroda T, Takahashi A, Kubo M, Minami S, Kamatani N et al. Genome-wide association study identifies genetic determinants of warfarin responsiveness for Japanese. Hum Mol Genet 2010;19:4735-44.
26. Ross KA, Bigham AW, Edwards M, Gozdzik A, Suarez-Kurtz G, Parra EJ. Worldwide allele frequency distribution of four polymorphisms associated with warfarin dose requirements. J Hum Genet 2010;55:582-9.
27. Loebstein R, Yonath H, Peleg D, Almog S, Rotenberg M, Lubetsky A et al. Interindividual variability in sensitivity to warfarin-Nature or nurture? Clin Pharmacol Ther 2001;70:159-64.
28. Gurwitz JH, Avorn J, Ross-Degnan D, Choodnovskiy I, Ansell J. Aging and the anticoagulant response to warfarin therapy. Ann Intern Med 1992;116:901-4.
29. Wittkowsky AK. Warfarin and other coumarin derivatives: pharmacokinetics, pharmacodynamics, and drug interactions. Semin Vasc Med 2003;3:221-30.
30. Shahin MH, Khalifa SI, Gong Y, Hammad LN, Sallam MT, El Shafey M et al. Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patients. Pharmacogenet Genomics 2011;21:130-5.
31. Lurie Y, Loebstein R, Kurnik D, Almog S, Halkin H. Warfarin and vitamin K intake in the era of pharmacogenetics. Br J Clin Pharmacol 2010;70:164-70.
32. Kim KH, Choi WS, Lee JH, Lee H, Yang DH, Chae SC. Relationship between dietary vitamin K intake and the stability of anticoagulation effect in patients taking long-term warfarin. Thromb Haemost 2010;104:755-9.